Papuloerythroderma of Ofuji (PEO) is a distinct clinical entity characterized by pruritic, erythroderma-like eruption comprising confluent papules sparing the skin folds (deck-chair sign).1,2 It occurs in elderly men and is often associated with blood eosinophilia and elevated serum immunoglobulin E (IgE) levels. Recent reports have suggested that T helper type 2 (TH2) cells could be important in the pathogenesis of PEO.3 Dupilumab is an interleukin (IL)-4 receptor α-antagonist that inhibits IL-4 and IL-13 signaling.4 This report describes 2 patients with PEO who were successfully treated with dupilumab.
Teraki Y, Taguchi R, Takamura S, Fukuda T. Use of Dupilumab in the Treatment of Papuloerythroderma of Ofuji. JAMA Dermatol. Published online June 19, 2019155(8):979–980. doi:10.1001/jamadermatol.2019.0946
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: